In this regard, it is important to note that the same AKT gene module that correlates with poor outcome in endocrine-treated ER+ breast cancer, was also able to predict a high activity score in breast cancer cell lines that were particularly sensitive to treatment with PI3K/AKT/mTOR inhibitors (Figure 6). The gene discussed is MTOR; the disease is breast carcinoma.